Association of aortic valve sclerosis with thrombin generation in hypertensive patients

Journal of Human Hypertension

Volumn 22, Issue 11, 2008, Pages 781-787

  Iida, M ^a   Yamamoto, M ^a   Yamazaki, M ^a   Sawaguchi, M ^b   Honjo, H ^c   Kodama, I ^c   Kamiya, K ^c  

^a NAGOYA CENTRAL HOSPITAL   (Japan)

^b SHIGA UNIVERSITY OF MEDICAL SCIENCE   (Japan)

^c NAGOYA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ATRIAL NATRIURETIC FACTOR; BRAIN NATRIURETIC PEPTIDE; D DIMER; FIBRIN; PROTHROMBIN; THROMBIN; VALSARTAN;

ADULT; AGE; AORTA FLOW; AORTA VALVE DISEASE; AORTA VALVE SCLEROSIS; ARTICLE; BLOOD FLOW VELOCITY; BLOOD PRESSURE REGULATION; CARDIOVASCULAR FUNCTION; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; DIASTOLE; DISEASE ASSOCIATION; FEMALE; GLOMERULUS FILTRATION RATE; HEART LEFT VENTRICLE SIZE; HUMAN; HYPERTENSION; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; PROTEIN SYNTHESIS; SEX DIFFERENCE; THROMBOGENESIS; TRANSTHORACIC ECHOCARDIOGRAPHY; TREATMENT DURATION;

AORTIC VALVE; BIOLOGICAL MARKERS; BLOOD PRESSURE; ECHOCARDIOGRAPHY; FEMALE; FOLLOW-UP STUDIES; HEART VALVE DISEASES; HEART VENTRICLES; HUMANS; HYPERTENSION; IMMUNOENZYME TECHNIQUES; MALE; MIDDLE AGED; PROGNOSIS; RETROSPECTIVE STUDIES; SCLEROSIS; THROMBIN;

EID: 54249133826     PISSN: 09509240     EISSN: 14765527     Source Type: Journal    
DOI: 10.1038/jhh.2008.68     Document Type: Article

References (24)

1. Olsen MH, Wachtell K, Bella JN, Gerdts E, Palmieri V, Nieminen MS Aortic valve sclerosis relates to cardiovascular events in patients with hypertension (a LIFE substudy). 2005; 95: 132-136.
2. Otto CM, Lind BK, Kitzman DW, Gersh BJ, Siscovick DS. Association of aortic-valve sclerosis with cardiovascular mortality and morbidity in the elderly [see comments]. 1999; 341: 142-147.
3. Freeman RV, Otto CM. Spectrum of calcific aortic valve disease: pathogenesis, disease progression, and treatment strategies. 2005; 111: 3316-3326.
4. Merlini PA, Bauer KA, Mannucci PM. Laboratory detection of the prethrombotic state. In: Verstraete M, Fuster V, Topol J (eds)., 2nd edn. Lippincott-Raven: Philadelphia, PA, 1998, pp 103-118.
5. Poggianti E, Venneri L, Chubuchny V, Jambrik Z, Baroncini LA, Picano E. Aortic valve sclerosis is associated with systemic endothelial dysfunction. 2003; 41: 136-141.
6. Lip GY. Hypertension and the prothrombotic state. 2000; 14: 687-690.
7. Minami T, Sugiyama A, Wu SQ, Abid R, Kodama T, Aird WC. Thrombin and phenotypic modulation of the endothelium. 2004; 24: 41-53.
8. Tracy RP. Thrombin, inflammation, and cardiovascular disease: An epidemiologic perspective. 2003; 124: 49S-57S.
9. Sechi LA, Zingaro L, Catena C, Casaccio D, De Marchi S. Relationship of fibrinogen levels and hemostatic abnormalities with organ damage in hypertension. 2000; 36: 978-985.
10. Jafri SM, Mammen EF, Masura J, Goldstein S. Effects of warfarin on markers of hypercoagulability in patients with heart failure. 1997; 134: 27-36.
11. Klapper L, Nachshon S, Zamir O, Zamir N. Thrombin stimulates atrial natriuretic peptide secretion from rat cardiac atrium. 1996; 278: 476-481.
12. Curry FR. Atrial natriuretic peptide: An essential physiological regulator of transvascular fluid, protein transport, and plasma volume. 2005; 115: 1458-1461.
13. Sechi LA, Zingaro L, Catena C, De Marchi S. Increased fibrinogen levels and hemostatic abnormalities in patients with arteriolar nephrosclerosis: Association with cardiovascular events. 2000; 84: 565-570.
14. Biasucci LM, Liuzzo G, Caligiuri G, Quaranta G, Andreotti F, Sperti G Temporal relation between ischemic episodes and activation of the coagulation system in unstable angina. 1996; 93: 2121-2127.
15. Nightingale AK, Horowitz JD. Aortic sclerosis: Not an innocent murmur but a marker of increased cardiovascular risk. 2005; 91: 1389-1393.
16. Patterson C, Stouffer GA, Madamanchi N, Runge MS. New tricks for old dogs: Nonthrombotic effects of thrombin in vessel wall biology. 2001; 88: 987-997.
17. Glembotski CC, Irons CE, Krown KA, Murray SF, Sprenkle AB, Sei CA. Myocardial alpha-thrombin receptor activation induces hypertrophy and increases atrial natriuretic factor gene expression. 1993; 268: 20646-20652.
18. Kohno M, Yasunari K, Yokokawa K, Murakawa K, Horio T, Takeda T. Inhibition by atrial and brain natriuretic peptides of endothelin-1 secretion after stimulation with angiotensin II and thrombin of cultured human endothelial cells. 1991; 87: 1999-2004.
19. Felmeden DC, Spencer CG, Chung NA, Belgore FM, Blann AD, Beavers DG Relation of thrombogenesis in systemic hypertension to angiogenesis and endothelial damage/dysfunction (a substudy of the Anglo-Scandinavian Cardiac Outcomes Trial [ASCOT]). 2003; 92: 400-405.
20. Dielis AW, Smid M, Spronk HM, Hamulyak K, Kroon AA, ten Cate H The prothrombotic paradox of hypertension: Role of the renin-angiotensin and kallikrein-kinin systems. 2005; 46: 1236-1242.
21. Koh KK, Chung WJ, Ahn JY, Han SH, Kang WC, Seo YH Angiotensin II type 1 receptor blockers reduce tissue factor activity and plasminogen activator inhibitor type-1 antigen in hypertensive patients: A randomized, double-blind, placebo-controlled study. 2004; 177: 155-160.
22. Muller DN, Mervaala EM, Dechend R, Fiebeler A, Park JK, Schmidt F Angiotensin II (ATM(1)) receptor blockade reduces vascular tissue factor in angiotensin II-induced cardiac vasculopathy. 2000; 157: 111-122.
23. Oubina MP, de Las Heras N, Vazquez-Perez S, Cediel E, Sanz-Rosa D, Ruilope LM Valsartan improves fibrinolytic balance in atherosclerotic rabbits. 2002; 20: 303-310.
24. Ridker PM, Danielson E, Rifai N, Glynn RJ. Valsartan, blood pressure reduction, and C-reactive protein: Primary report of the Val-MARC trial. 2006; 48: 73-79.